Abstract
Pidotimod has been shown to exhibit immunomodulatory activities and exert protective effects against bacterial infections. This study aimed at evaluating the protective effects of pidotimod against Salmonella infections in mice. C57BL/6 mice were assigned into 6 groups: Control group; Low-dose pidotimod group (PL, 12.5 μg/gram of body weight); High-dose pidotimod group (PH, 200 μg/gram of body weight); ST infection group (ST); Low-dose pidotimod and ST infection group (PL + ST); and High-dose pidotimod and ST infection group (PH + ST). Mice in each group were gavaged 200 μL ddH2O with or without pidotimod per day before Salmonella enterica Typhimurium (ST) challenge. It was shown that high-dose pidotimod pretreatment alleviated weight loss, inhibited ST associated spleen and liver damage, suppressed serum TNF-α levels and elevated IL-10 levels. Moreover, it elevated CD4+/CD8+ T cell ratio in the blood. In conclusion, oral pidotimod can effectively enhance clinical responses to Salmonella infections.
Similar content being viewed by others
Explore related subjects
Discover the latest articles, news and stories from top researchers in related subjects.Avoid common mistakes on your manuscript.
Introduction
Pidotimod ((R)-3-[(S)-(5-oxo-2-pyrrolidinyl) carbonyl]-thiazolidine-4-carboxylic acid) is a synthetic dipeptide molecule with biological and immunological activities on both innate and adaptive immune systems (Riboldi et al. 2009). Among its functions, it enhances and stimulates immune cell functions, including neutrophil phagocytosis (Auteri et al. 1992; Ferrario et al. 2015); it induces phenotypic and functional maturation of mucosal dendritic cells; it plays a crucial role in the cross-talk between innate and adaptive immunity (Puggioni et al. 2019); and, it stimulates protective effects against bacterial and viral infections without any therapeutic interactions (Coppi et al. 1994; Manzardo et al. 1994). Regarding its antibacterial mechanisms, pidotimod can upregulate the expression of TLR2 (Toll Like Receptors), with a significant increase in NF-κB protein expression and NF-κB nuclear translocation (Carta et al. 2013). Moreover, pidotimod promotes the mRNA expression levels of antimicrobial peptides and augments the expression of genes involved in inflammatory responses (Esposito et al. 2015). All in all, pidotimod had a certain antibacterial ability.
Salmonella, a member of the Enterobacteriaceae family (Bopp 1999), causes enteric diseases in humans and animals (Dougan et al. 2011). Globally, Salmonella are highly associated with foodborne diseases and impair the quality of livestock products in animal husbandry (Anderson and Kendall 2017; Zhen et al. 2018). Salmonella enterica Typhimurium (ST), a frequent cause of acute and self-limiting foodborne diarrhea, is an ideal study model that has been used to reveal key principles of enteropathogenic infections (Wotzka et al. 2017). This study aimed at evaluating the efficacy of pidotimod against Salmonella infections.
Materials and Methods
Study Animals and Ethical Statements
Healthy male C57BL/6 mice aged 5–6 weeks were purchased from Slac Animal Inc. (Shanghai, China) and housed in the environment without pathogenic microorganisms. Mice were maintained at 20–25 ℃ with a 12:12, light/dark cycle and given adequate standard feed and drinking water. The experimental procedures involving mice were approved by the Institutional Animal Care and Use Committee of Zhejiang University.
Bacterial Strains and Culture Conditions
Salmonella Typhimurium CMCC 50115 (ST), which is an attenuated strain (Wei et al. 2019), was obtained from the Institute of Preventive Veterinary Medicine, Zhejiang University (China). It was inoculated into Luria–Bertani (LB) medium and incubated at 37 ℃ with shaking at 180 rpm/min overnight. The ST liquid culture was centrifuged at 5000 rpm for 5 min and concentrated to 2 × 109 CFU/mL in sterile PBS.
Experimental Design
Healthy male C57BL/6 mice were randomly assigned into 6 groups (n = 10 per group): Control, Low-dose pidotimod group (PL), High-dose pidotimod group (PH), ST infection group (ST), Low-dose pidotimod and ST infection group (PL + ST), as well as High-dose pidotimod and ST infection group (PH + ST).
The experiment was performed in two phases. The first phase involved prevention for 14 days. Mice in the control and ST groups were gavaged 200 μL ddH2O per day. Mice in the PL and PL + ST groups were gavaged 200 μL ddH2O containing pidotimod (12.5 μg per gram body weight) on the basis of normal drinking water per day, while PH and PH + ST groups administered with 200 μg/body weight of pidotimod. Weight changes were measured after every two days. The second phase involved ST infection which was immediately after the end of the prevention stage. Mice in the ST, PL + ST and PH + ST groups were inoculated with 4 × 108 CFU of ST in 200 μL PBS by gavage, while the other groups were administered with 200 μL of PBS. After two days of infection, mice were weighed and the samples collected after euthanized.
Preparation of Tissue Samples
The spleen, liver and colon were collected and cleaned with normal saline to remove blood and mesangial membrane. The spleen and liver were weighed to calculate the splenic and liver indices [splenic/liver index = spleen/liver weight (mg) divided by body weight (g)]. The procedure of making pathological sections used in this study was performed as previously described (Güçlü et al. 2011) with some modifications. Briefly, spleen, liver and colon sections were fixed in 4% paraformaldehyde. Hematoxylin–eosin (H&E) staining of the sections was performed through dehydration, paraffin embedding, slicing, dewaxing, staining and dehydration sealing. Histopathological sections were observed using an optical microscope.
Analysis of Bacterial Load in the Spleen
The spleen was placed in a sterile environment, rinsed with pre-cooled sterile PBS, weighted and homogenized. The homogenate was plated on Salmonella–Shigella agar after serial dilutions and incubated. Colonies were counted after 24 h.
Determination of GOT and GPT in the Liver and Serum
A tissue homogenate of the liver was prepared. Subsequently, glutamic pyruvic transaminase (GPT) and glutamic oxaloacetic transaminase (GOT) activities were determined in the tissue homogenate and serum according to the manufacturer’s protocols (Nanjing Jiancheng Bioengineering Institute, China).
Serum Preparation and Cytokine Determination
Blood was collected from the femoral artery of mice and kept still at 4 ℃ overnight. Serum was separated by centrifugation at 3000 g for 20 min at 4 ℃. Cytokine (TNF-α and IL-10) concentrations in the serum were determined using ELISA kits (eBioscience, USA) according to the manufacturer’s instructions.
Flow Cytometry Analysis of Blood Lymphocytes
After two days of Salmonella infection, mononuclear lymphocytes from mice in the ST-infected groups were extracted as previously described (Trobonjaca et al. 2002). The lymphocyte suspension was blocked using 5% goat serum for 15 min and co-incubated with anti-mouse CD3 (FITC) (eBioscience, USA) and anti-mouse CD4 (PE) (eBioscience, USA) or anti-mouse CD3 (FITC) and anti-mouse CD8 (PE) (eBioscience, USA) at 4 ℃ for 30 min, respectively. Stained cells were analyzed by FACS using an LSR II Analyzer (BD). Blood CD3+CD4+ to CD3+CD8+ (CD4+/ CD8+) ratios were then calculated.
Statistical Analysis
Data were analyzed using the IBM SPSS Statistics 22 and represented as mean ± SD. Comparison of means between two groups was done using the Student’s t test, while comparisons of means for multiple groups were performed by one-way ANOVA. P < 0.05 was considered significant while P < 0.01 was considered extremely significant. The OriginPro 9.0 software was used to draw graphics.
Results
Pidotimod Alleviated ST Infection in Mice
Pidotimod administration (in both PH and PL groups) did not exert a significant effect on body weight of mice before ST challenge (P > 0.05) (Fig. 1a). Regarding the protective effect of pidotimod against ST infection, compared to mice in the ST group, weight loss in the PH + ST group was significant (P < 0.05) (Fig. 1b). Moreover, mice in the PL + ST group did not achieve a good effect on infection relief (P > 0.05). These results reveal that high-dose pidotimod can effectively alleviate ST infection associated weight loss.
There was no significant difference in splenic index between mice in pidotimod treated groups (both of the PH and PL groups) and the control group (P > 0.05) (Fig. 1c). After two days of infection, splenic index of mice in the ST group was significantly higher than that of the control group (P < 0.05) while the splenic index of mice in the PH + ST group was significantly lower than that of the ST group (P < 0.05) (Fig. 1c). Pidotimod did not exert any significant effects on the splenic index of normal mice. However, high-dose pidotimod relieved ST infection associated increase in splenic index. Furthermore, compared to the control group, high-dose pidotimod was shown to significantly reduce the liver index (P < 0.05) (Fig. 1d). The liver index of mice in the ST group was found to be significantly elevated (P < 0.05) while liver indices of mice in the PL + ST and PH + ST groups were significantly lower than that of the ST group (P < 0.05) (Fig. 1d). These results imply that pidotimod could effectively relieve the elevated liver index caused by ST infection.
Regarding Salmonella burden in the spleen, although pidotimod suppressed the quantities of Salmonella in mice spleen, the differences among groups were not significant (P > 0.05) (Fig. 1e).
Pidotimod Alleviated ST Infection Associated Tissue Structure Damage
Spleen structures of mice in the control group were clear with complete shapes (Fig. 2a). Moreover, the shape of the lymphoid follicles, which occurred in large numbers, was clear. Splenic morphologies in the PL and PH groups were similar to that of the control mice. After 2 days of infection, splenic structures of mice in the ST group were found to have been severely damaged, lymphoid follicles had shrunk, while the number of lymphoid follicles had also reduced, when compared to the control group. Splenic structures of mice in the PL + ST group was similar to that of the ST group, but without lymphoid follicles. However, the splenic structure of mice in the PH + ST group was better than that of the ST group, the texture was relatively clear while the lymphoid follicles were intact. These results imply that high-dose pidotimod could significantly alleviate ST infection associated splenic damage and exert a preventive effect.
There was no significant difference in liver structures between mice in the PL and PH groups compared to the control mice (Fig. 2b). After 2 days of infection, acute inflammatory cell infiltration and focal necrosis were observed in the hepatocytes of mice in the ST group. In addition, ST induced acute inflammatory cell infiltration was found to be significantly alleviated in the pidotimod groups (PH + ST and PL + ST groups). These results show that pidotimod can significantly alleviate ST infection induced liver inflammation.
Colon morphologies of mice in the control, PL and PH groups were complete with clear mucosal and gland structures. Moreover, there was no inflammatory cell infiltration (Fig. 2c). After 2 days of infection, inflammatory cell infiltration was elevated in the colonic mucosa and submucosa of mice in the ST group, while the structure of the gland was not clear. Colonic mucosa was clear while inflammatory cell infiltration was inhibited among the pidotimod groups (PH + ST and the PL + ST groups), compared to the ST group. These findings imply that pidotimod alleviates ST infection associated colon tissue lesions.
Pidotimod Alleviated ST Associated Increase in GOT and GPT Activities in Serum
Compared to mice in the control group, GOT activities in the liver of mice in the pidotimod groups (PH and PL groups) were significantly decreased (P < 0.05) (Fig. 3a). At the same time, pidotimod administration significantly reduced the activities of GOT and GPT in the serum (P < 0.05) (Fig. 3c and d). After two days of infection, compared to mice in the ST group, pretreatment with high-dose pidotimod was shown to significantly inhibit the elevated GOT and GPT activities in the serum (P < 0.05) (Fig. 3c, d). Therefore, to a certain extent, ST infection-induced liver damage can be alleviated by pidotimod.
Pidotimod Inhibited the Secretion of TNF-α and Promoted IL-10 Secretion in ST-Infected Mice
Serum TNF-α levels of normal mice were too low to be detected (Fig. 4a). After two days of infection, TNF-α levels in serum of mice in the ST group was shown to have sharply increased. However, TNF-α levels of mice in the PL + ST group were significantly low than those of the ST group (P < 0.05). Higher IL-10 levels were recorded in normal mice (significantly higher in the PH group, P < 0.05) (Fig. 4b). After two days of infection, IL-10 levels of mice in the PH + ST group were significantly elevated when compared to the ST group (P < 0.05). These results indicate that higher doses of pidotimod enhances the secretion of IL-10 in normal mice and ST-infected mice, and inhibits the secretion of TNF-α in ST-infected mice.
Pidotimod Elevated the CD4+/CD8+ Ratio in the Blood of ST-Infected Mice
Flow cytometry revealed that, after two days of infection, the CD4+/CD8+ cell ratios in the blood of pidotimod administered groups (PH + ST and the PL + ST groups) were significantly elevated compared to those of the ST group (P < 0.05) (Fig. 5).
Discussion
This study revealed the effects of pidotimod in normal and ST-infected mice. Other studies have documented that active dosages of pidotimod against bacterial infections in mice range from 0.01 to 100 µg/g (Coppi et al. 1994). As for our study, we used two experimental concentrations (12.5 μg/g and 200 μg/g). We found that although pidotimod did not exert a significant effect on body weights in normal mice, pretreatment with a high-dose of pidotimod alleviated ST infection induced weight loss. These results are consistent with those of Coppi et al. who concluded that pretreatment with pidotimod has protective effects against bacterial infections in mice (Coppi et al. 1994). It is worth mentioning that the spleen plays an important role in resistance to infection (Morris and Bullock 1919), and the splenic index reflects immune functions of the body during infections (Hadidi et al. 2008). We found that high-dose pidotimod relieved the increase in splenic index caused by pathogenic microbe infection and the acute inflammatory cell infiltration. However, in our study, pidotimod could not significantly reduce Salmonella burden in the spleen, which was an interesting phenomenon. In addition, Salmonella can migrate to the liver when the intestinal barrier is destroyed (Mathur et al. 2012). It also attacks the liver, impairing its functions (Esposito et al. 2018). We found that pidotimod could also relieve ST infection associated increase in liver indices of mice. Moreover, pidotimod alleviated ST infection associated liver inflammation and colon tissue lesions. These results suggest that it could alleviate the tissue damage caused by Salmonella infections, in tandem with the findings of Zhao et al. who reported that pidotimod could significantly decrease the number of medium-sized inflammatory foci of neutrophil infiltrates in the liver of mice after parasitic infections (Zhao et al. 2013).
Infection with pathogenic microbes, such as Salmonella, often leads to a significant inflammatory response (Dube et al. 2001). In this study, pidotimod suppressed the serum level of pro-inflammatory cytokine, TNF-α, and elevated the level of anti-inflammatory cytokine, IL-10. It has been reported that pidotimod can modify the immune responses that are triggered by TLR ligands and attenuate TLR-induced inflammation (Fogli et al. 2014). In addition, other studies have shown that pidotimod can be used in the treatment of inflammation-associated diseases (Caruso and Fiorentini 2016). We postulate that one of the ways in which pidotimod resists ST infection is by relieving inflammation. GOT and GPT can be used as important liver injury indicators (Huang et al. 2006). We found that high doses of pidotimod relieved elevated serum GOT and GPT levels after ST infection, implying that pidotimod may be effective in alleviating Salmonella-induced liver damage.
CD4+ T cells play important roles in immune protection (Zhu and Paul, 2008). CD8+ T cells also respond to viral infections and participate in defenses against bacterial and protozoal infections (Wong and Pamer, 2003). The CD4+/CD8+ T cell ratio is closely associated with the immune ability of the body, and is increasingly becoming a valuable indicator of immune activation (Bruno et al. 2017). A high ratio indicates that the immune function is relatively strong (Amadori et al. 1995), while a decreased CD4+/CD8+ ratio is associated with impaired cellular immunity (Wang et al. 2017). Pidotimod stimulated cellular immune responses by promoting lymphocyte proliferation (Fogli et al. 2014). In this experiment, pidotimod could significantly increase the CD4+/CD8+ T cell ratio in the blood of ST-infected mice, implying that pidotimod enhances immune cell functions against ST infection. This finding is consistent with that of other studies that showed that pidotimod improved the level of T-lymphocyte subtypes in recurrent respiratory tract infections (Niu et al. 2019).
Conclusions
A high dose of pidotimod (200 μg pidotimod per gram of body weight) exhibits protective effects against ST infection in mice. These findings highlight the significance of pidotimod as a positive immunomodulator in defense against ST challenge and provides a theoretical basis for the application of pidotimod in animal husbandry to resist bacterial infections.
References
Amadori A, Zamarchi R, De Silvestro G, Forza G, Cavatton G, Danieli GA, Clementi M, Chieco-Bianchi L (1995) Genetic control of the CD4/CD8 T-cell ratio in humans. Nat Med 1:1279–1283
Anderson CJ, Kendall MM (2017) Salmonella enterica Serovar Typhimurium strategies for host adaptation. Front Microbiol 8:1983
Auteri A, Pasqui AL, Bruni F, Saletti M, Di Renzo M, Bova G (1992) Effect of pidotimod, a new immunostimulating agent, on some aspects of immune response vitro study. Pharmacol Res 26(Suppl 2):196–197
Bopp CA (1999) Escherichia, Shigella, and Salmonella. Manual of clinical microbiology. SM Press, Washington
Bruno G, Saracino A, Monno L, Angarano G (2017) The revival of an “old” marker: CD4/CD8 ratio. AIDS Rev 19:81–88
Carta S, Silvestri M, Rossi GA (2013) Modulation of airway epithelial cell functions by Pidotimod: NF-kB cytoplasmatic expression and its nuclear translocation are associated with an increased TLR-2 expression. Ital J Pediatr 39:29
Caruso A, Fiorentini S (2016) Pidotimod for use in the treatment of inflammation-associated diseases. Google Patents
Coppi G, Falcone A, Manzardo S (1994) Protective effects of pidotimod against experimental bacterial infections in mice. Arzneimittelforschung 44:1417–1421
Dougan G, John V, Palmer S, Mastroeni P (2011) Immunity to salmonellosis. Immunol Rev 240:196–210
Dube PH, Revell PA, Chaplin DD, Lorenz RG, Miller VL (2001) A role for IL-1 alpha in inducing pathologic inflammation during bacterial infection. Proc Natl Acad Sci USA 98:10880–10885
Esposito S, Garziano M, Rainone V, Trabattoni D, Biasin M, Senatore L, Marchisio P, Rossi M, Principi N, Clerici M (2015) Immunomodulatory activity of pidotimod administered with standard antibiotic therapy in children hospitalized for community-acquired pneumonia. J Transl Med 13:1–10
Esposito E, Campolo M, Casili G, Lanza M, Franco D, Filippone A, Peritore AF, Cuzzocrea S (2018) Protective effects of xyloglucan in association with the polysaccharide gelose in an experimental model of gastroenteritis and urinary tract infections. Int J Mol Sci 19:1844
Ferrario BE, Garuti S, Braido F, Canonica GW (2015) Pidotimod: the state of art. Clin Mol Allergy 13:8
Fogli M, Caccuri F, Iaria ML, Giagulli C, Corbellini S, Campilongo F, Caruso A, Fiorentini S (2014) The immunomodulatory molecule pidotimod induces the expression of the NOD-like receptor NLRP12 and attenuates TLR-induced inflammation. J Biol Regul Homeost Agents 28:753–766
Güçlü BK, Kara K, Çakır L, Çetin E, Kanbur M (2011) Carnitine supplementation modulates high dietary copper-induced oxidative toxicity and reduced performance in laying hens. Biol Trace Elem Res 144:725–735
Hadidi S, Glenney GW, Welch TJ, Silverstein JT, Wiens GD (2008) Spleen size predicts resistance of rainbow trout to Flavobacterium psychrophilum challenge. J Immunol 180:4156–4165
Huang X, Choi Y, Im H, Yarimaga O, Yoon E, Kim H (2006) Aspartate aminotransferase (AST/GOT) and alanine aminotransferase (ALT/GPT) detection techniques. Sensors-Basel 6:756–782
Manzardo S, Falcone A, Pinzetta A, Ieva G, Coppi G (1994) General pharmacology of pidotimod and testing for drug interactions. Arzneimittelforschung 44:1441–1447
Mathur R, Oh H, Zhang D, Park SG, Seo J, Koblansky A, Hayden MS, Ghosh S (2012) A mouse model of Salmonella typhi infection. Cell 151:590–602
Morris DH, Bullock FD (1919) The importance of the spleen in resistance to infection. Ann Surg 70:513–521
Niu H, Wang R, Jia Y, Cai Y (2019) Pidotimod, an immunostimulant in pediatric recurrent respiratory tract infections: a meta-analysis of randomized controlled trials. Int Immunopharmacol 67:35–45
Puggioni F, Alves-Correia M, Mohamed MF, Stomeo N, Mager R, Marinoni M, Racca F, Paoletti G, Varricchi G, Giorgis V, Melioli G, Canonica GW, Heffler E (2019) Immunostimulants in respiratory diseases: focus on Pidotimod. Multidiscip Respir Med 14:31
Riboldi P, Gerosa M, Meroni PL (2009) Pidotimod: a reappraisal. Int J Immunopathol Pharmacol 22:255–262
Trobonjaca Z, Kroger A, Stober D, Leithauser F, Moller P, Hauser H, Schirmbeck R, Reimann J (2002) Activating immunity in the liver. II. IFN-beta attenuates NK cell-dependent liver injury triggered by liver NKT cell activation. J Immunol 168:3763–3770
Wang K, Shen T, Siegal GP, Wei S (2017) The CD4/CD8 ratio of tumor-infiltrating lymphocytes at the tumor-host interface has prognostic value in triple-negative breast cancer. Hum Pathol 69:110–117
Wei S, Huang J, Liu Z, Wang M, Zhang B, Lian Z, Guo Y, Han H (2019) Differential immune responses of C57BL/6 mice to infection by Salmonella enterica serovar Typhimurium strain SL1344, CVCC541 and CMCC50115. Virulence 10:248–259
Wong P, Pamer EG (2003) CD8 T cell responses to infectious pathogens. Annu Rev Immunol 21:29–70
Wotzka SY, Nguyen BD, Hardt W (2017) Salmonella typhimurium diarrhea reveals basic principles of enteropathogen infection and disease-promoted DNA exchange. Cell Host Microbe 21:443–454
Zhao Y, Huang B, Huang S, Zheng H, Li YQ, Lun ZR, Shen J, Wang Y, Kasper LH, Lu F (2013) Evaluation of the adjuvant effect of pidotimod on the immune protection induced by UV-attenuated Toxoplasma gondii in mouse models. Parasitol Res 112:3151–3160
Zhen W, Shao Y, Gong X, Wu Y, Geng Y, Wang Z, Guo Y (2018) Effect of dietary Bacillus coagulans supplementation on growth performance and immune responses of broiler chickens challenged by Salmonella enteritidis. Poultry Sci 97:2654–2666
Zhu J, Paul WE (2008) CD4 T cells: fates, functions, and faults. Blood 112:1557–1569
Author information
Authors and Affiliations
Contributions
XZ and LF conceptualized the experiments; YZ and LF performed the experiments; YZ wrote the original draft; YZ and LF analyzed the data; XY and the rest of the authors revised the manuscript. All authors have read and agreed to the published version of the manuscript.
Corresponding authors
Ethics declarations
Conflict of interest
The authors declare no conflict of interest.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Zhou, Y., Ye, X., Wang, B. et al. Protective Effects of Pidotimod Against Salmonella Infections. Int J Pept Res Ther 27, 1605–1613 (2021). https://doi.org/10.1007/s10989-021-10186-z
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10989-021-10186-z